...
首页> 外文期刊>Life sciences >Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
【24h】

Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.

机译:异黄酮衍生物ipriflavone的药代动力学,经静脉和口服给予大鼠肝和肠首过效应。

获取原文
获取原文并翻译 | 示例

摘要

Pharmacokinetic parameters of ipriflavone were evaluated after intravenous administration of spray-dried ipriflavone with polyvinylpyrrolidone, SIP (5, 10, 20, and 40 mg/kg as ipriflavone) and oral administration of SIP (50, 100, and 200 mg/kg as ipriflavone) to rats. The hepatic, gastric, and intestinal first-pass effects of ipriflavone were also measured after intravenous, intraportal, intraduodenal, and oral administration of SIP (20 or 50 mg/kg as ipriflavone) to rats. After intravenous and oral administration, the pharmacokinetic parameters of ipriflavone were dose-independent. The extent of absolute oral bioavailability (F) was also independent of oral doses; the mean F value was approximately 24%. Considering the amount of unchanged ipriflavone recovered from 24-hr gastrointestinal tract (the mean value was approximately 12%), the low F values could be due to the hepatic, gastric, and/or intestinal first-pass effects. Based on total body clearance (CL) data of ipriflavone after intravenous administration, the first-pass effect in the heart and lung could be almost negligible, if any, in rats. Approximately 30% of ipriflavone absorbed into the portal vein was eliminated by liver (hepatic first-pass effect) based on intravenous and intraportal administration of SIP. The area under the plasma concentration-time curve from time zero to time infinity (AUC) values after oral administration and intraduodenal instillation of SIP, 50 mg/kg as ipriflavone, were not significantly different, but the values were significantly smaller (129 and 116 microg ml/min) than that after intraportal administration of SIP, 20 mg/kg as ipriflavone (513 microg ml/min based on 50 mg/kg), indicating that gastric first-pass effect of ipriflavone was negligible, but intestinal first-pass effect was considerable in rats. Therefore, the low F value of ipriflavone after oral administration to rats was mainly due to intestinal first-pass effect. The hepatic first-pass effect and incomplete absorption of ipriflavone from rat gastrointestinal tract could also contributed to the low F in rats.
机译:静脉注射喷雾干燥的依普黄酮与聚乙烯吡咯烷酮,SIP(依普黄酮为5、10、20和40 mg / kg)并口服SIP(依普黄酮为50、100和200 mg / kg)后评估依普黄酮的药代动力学参数)给老鼠。在静脉,门静脉内,十二指肠内和口服给予大鼠SIP(20或50 mg / kg的依普黄酮)后,还测定了依普黄酮对肝,胃和肠的首过效应。静脉和口服给药后,依普黄酮的药代动力学参数与剂量无关。口服绝对生物利用度(F)也与口服剂量无关;平均F值约为24%。考虑到从24小时胃肠道中回收的不变的依普黄酮的量(平均值约为12%),低F值可能归因于肝,胃和/或肠的首过效应。根据静脉注射后依普黄酮的全身清除率(CL)数据,在大鼠中,心脏和肺部的首过效应几乎可以忽略不计。基于静脉内和门静脉内注射SIP,约30%的依普黄酮吸收到门静脉中后被肝脏清除(肝首过效应)。口服和十二指肠内滴注SIP后的血浆浓度-时间曲线从零时点到无限时点(AUC)值的区域,依普黄酮的剂量为50 mg / kg并没有显着差异,但值显着较小(129和116) (微克毫升/分钟)比经门静脉注射SIP后为20毫克/千克的依普黄酮(513微克毫升/分钟,基于50毫克/千克),表明依普黄酮的胃首过效应可忽略不计,但肠道首过在大鼠中效果显着。因此,口服给予大鼠后,依普黄酮的低F值主要是由于肠道的首过效应。肝首过效应和ipriflavone从胃肠道的不完全吸收也可能是导致大鼠低F的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号